中国科技核心期刊
CN:31-1600/Q
ISSN:1004-0374
“健康与疾病的免疫”国际学术研讨会通知      关于有网站冒充本刊网站的声明
《生命科学》 2004, (2): 90-
胰高血糖素样肽1受体——治疗糖尿病新药的研究热点
周彩红,胡 慧,王明伟*
国家新药筛选中心,中国科学院上海药物研究所,上海 201203
摘 要:胰高血糖素样肽1 (glucagon-like peptide-1, GLP-1)与胰岛素分泌和糖代谢调节密切相关。GLP-1与其受体(GLP-1 receptor, GLP-1R)结合后,主要通过cAMP和PI3K两条信号途径,促进胰岛素的分泌,刺激胰岛b细胞的增殖和分化。对GLP-1R结构和信号传导机制的研究,有助于了解其在糖尿病病理进程中的作用,为开发新型糖尿病治疗药物指明方向。
关键词:胰高血糖素样肽1;胰岛素;糖尿病;信号传导
 
Glucagon-like peptide-1 receptor: a novel therapeutic target for diabetes
ZHOU Cai-Hong, HU Hui, WANG Ming-Wei*
National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
Abstract: Glucagon-like peptide-1 is a peptide hormone that controls insulin secretion and glucose metabolism. Following binding with its receptor, mainly through cAMP and PI3K signal pathways, GLP-1 stimulates glucose-dependant insulin secretion, b-cell proliferation and enhances the differentiation of new b-cells from progenitor cells.  Studies on GLP-1R structure and signal transduction pathways would further our understanding on its role in  the pathogenesis of type 2 diabetes mellitus, thereby developing new therapeutic strategies for diabetes.
Key words: glucagon-like peptide-1; insulin; diabetes; signal transduction
 
首页 | 刊物简介 | 编委会 | 投稿须知 | 广告业务 | 过刊浏览 | 联系我们
中国科学院上海生命科学信息中心《生命科学》编辑部
Copyright © 2012-2015 《生命科学》编辑部 All Rights Reserved.
沪ICP备05033115号-30
您是第2954702 位访问者,欢迎!